Kenneth G Nepple

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1485423/publications.pdf

Version: 2024-02-01

96 papers 2,439 citations

257450 24 h-index 223800 46 g-index

97 all docs

97 docs citations

97 times ranked 3076 citing authors

#	Article	IF	CITATIONS
1	Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 9.e1-9.e7.	1.6	9
2	Sequential intravesical gemcitabine and docetaxel for BCG-na \tilde{A} -ve high-risk nonmuscle-invasive bladder cancer Journal of Clinical Oncology, 2022, 40, 497-497.	1.6	O
3	Inherited germline variants in urothelial cancer: A multicenter whole-exome sequencing analysis Journal of Clinical Oncology, 2022, 40, 451-451.	1.6	O
4	Sequential intravesical valrubicin and docetaxel for the treatment of nonmuscle invasive bladder cancer Journal of Clinical Oncology, 2022, 40, 496-496.	1.6	0
5	Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer Journal of Clinical Oncology, 2022, 40, 573-573.	1.6	O
6	Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non–Muscle-Invasive Bladder Cancer. Journal of Urology, 2022, 208, 969-977.	0.4	5
7	Quantitative Test–Retest Measurement of ⁶⁸ Ga-PSMA-HBED-CC in Tumor and Normal Tissue. Journal of Nuclear Medicine, 2020, 61, 1145-1152.	5.0	23
8	Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma. PLoS ONE, 2020, 15, e0233795.	2. 5	3
9	Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2020, 203, 902-909.	0.4	90
10	Title is missing!. , 2020, 15, e0233795.		0
11	Title is missing!. , 2020, 15, e0233795.		O
12	Title is missing!. , 2020, 15, e0233795.		0
13	Title is missing!. , 2020, 15, e0233795.		O
14	Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World Journal of Urology, 2019, 37, 107-114.	2.2	50
15	Compliance With American Urological Association Guidelines for Nonmuscle Invasive Bladder Cancer Remains Poor: Assessing Factors Associated With Noncompliance and Survival in a Rural State. Urology, 2019, 132, 150-155.	1.0	12
16	Enhancing Identification and Management of Hospitalized Patients Who Are Malnourished: AÂPilot Evaluation of Electronic Quality Improvement Measures. Journal of the Academy of Nutrition and Dietetics, 2019, 119, S32-S39.	0.8	12
17	The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies. Cancer Causes and Control, 2019, 30, 871-876.	1.8	21
18	Why men with a low-risk prostate cancer select and stay on active surveillance: A qualitative study. PLoS ONE, 2019, 14, e0225134.	2.5	11

#	Article	IF	CITATIONS
19	Infectious Complications of Conventional Laparoscopic <i>vs</i> Robotic Laparoscopic Prostatectomy: A Systematic Literature Review and Meta-Analysis. Journal of Endourology, 2019, 33, 179-188.	2.1	4
20	Malnutrition Diagnosis during Adult Inpatient Hospitalizations: Analysis of a Multi-Institutional Collaborative Database of Academic MedicalÂCenters. Journal of the Academy of Nutrition and Dietetics, 2018, 118, 125-131.	0.8	72
21	Evaluating the Effectiveness, Efficiency and Safety of Telemedicine for Urological Care in the Male Prisoner Population. Urology Practice, 2018, 5, 44-51.	0.5	28
22	Managing the High Incidence of Testicular Pain and Pathology in PrisonersÂwith Telemedicine. Urology Practice, 2018, 5, 372-376.	0.5	2
23	Optimizing Nutrition Prior to Radical Cystectomy. Current Urology Reports, 2018, 19, 99.	2.2	12
24	Autoimmune retinopathy and optic neuropathy associated with enolase-positive renal oncocytoma. American Journal of Ophthalmology Case Reports, 2018, 12, 55-60.	0.7	7
25	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. European Urology Oncology, 2018, 1, 143-148.	5.4	19
26	Editorial Comment. Journal of Urology, 2018, 200, 300-300.	0.4	0
27	Taking the Procedure to the Patient: Increasing Access to Urological Procedural Care through Outreach. Urology Practice, 2017, 4, 335-341.	0.5	2
28	Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder Cancer. Journal of Urology, 2017, 198, 511-519.	0.4	66
29	Trends in Operating Room Assistance for Major Urologic Surgical Procedures: An Increasing Role for Advanced Practice Providers. Urology, 2017, 106, 76-81.	1.0	11
30	Obesity as defined by waist circumference but not body mass index is associated with higher renal mass complexity. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 661.e1-661.e6.	1.6	14
31	Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 670.e7-670.e14.	1.6	17
32	Increasing Use of Advanced Practice Providers for Urological Office Procedural Care in the United States. Urology Practice, 2017, 4, 169-175.	0.5	6
33	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 1175-1182.	4.3	14
34	Variation in results release and patient portal access to diagnostic test results at an academic medical center. Journal of Pathology Informatics, 2017, 8, 45.	1.7	28
35	Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Current Urology Reports, 2016, 17, 38.	2.2	25
36	Impact of Robotic Fellowship Experience on Perioperative Outcomes of Robotic-Assisted Laparoscopic Partial Nephrectomy. Current Urology, 2016, 9, 19-23.	0.6	4

3

#	Article	IF	CITATIONS
37	Intravesical and alternative bladder-preservation therapies in the management of non–muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 279-289.	1.6	15
38	Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2015, 1, 65-72.	0.4	69
39	Complications following primary and revision transsphenoidal surgeries for pituitary tumors. Laryngoscope, 2015, 125, 311-317.	2.0	30
40	Does Routine Pathology Analysis of Adult Circumcision Tissue Identify Penile Cancer?. Urology, 2015, 85, 1431-1435.	1.0	7
41	Reply. Urology, 2015, 85, 1435.	1.0	0
42	Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy. BMC Urology, 2015, 15, 45.	1.4	15
43	Gleason 6 Prostate Cancer: Translating Biology into Population Health. Journal of Urology, 2015, 194, 626-634.	0.4	75
44	Reply to Michael Froehner's Letter to the Editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. Eur Urol 2013;64:372–8. European Urology, 2014, 65, e42.	1.9	0
45	IgG4 Related Disease of the Ureter (Inflammatory Pseudotumor). Journal of Urology, 2014, 191, 1126-1127.	0.4	13
46	Analysis of Intracorporeal Compared with Extracorporeal Urinary Diversion After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. European Urology, 2014, 65, 340-347.	1.9	242
47	Complications of primary and revision functional endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope, 2014, 124, 838-845.	2.0	148
48	Vaccine immunotherapy for prostate cancer: from mice to men. Immunologic Research, 2014, 59, 229-235.	2.9	3
49	Efficacy of robotâ€assisted radical cystectomy (<scp>RARC</scp>) in advanced bladder cancer: results from the <scp>I</scp> nternational <scp>R</scp> adical <scp>C</scp> ystectomy <scp>C</scp> onsortium (<scp>IRCC</scp>). BJU International, 2014, 114, 98-103.	2.5	14
50	Routine Pathology Evaluation of Hydrocele and Spermatocele Specimens is Associated with Significant Costs and No Identifiable Benefit. Journal of Urology, 2014, 192, 1179-1182.	0.4	8
51	Defining the Potential of Neoadjuvant Chemotherapy Use as a Quality Indicator for Bladder Cancer Care. Journal of Urology, 2014, 192, 43-49.	0.4	8
52	Benchtop evaluation of pressure barrier insufflator and standard insufflator systems. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 333-338.	2.4	36
53	Reply from Authors re: Manfred P. Wirth, Johannes Huber. What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes. Eur Urol 2013;64:58–9. European Urology, 2013, 64, 60-61.	1.9	0
54	Prostate Cancer Chemoprevention. Seminars in Oncology, 2013, 40, 276-285.	2.2	23

#	Article	IF	Citations
55	Concordance of preoperative prostate endorectal MRI with subsequent prostatectomy specimen in high-risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 601-606.	1.6	17
56	Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. European Urology, 2013, 64, 52-57.	1.9	189
57	Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 894-898.	1.6	46
58	Randomized Controlled Trial of Oxybutynin Extended Release Versus Placebo for Urinary Symptoms During Intravesical Bacillus Calmette-GuÃ@rin Treatment. Journal of Urology, 2013, 189, 1268-1274.	0.4	22
59	Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. European Urology, 2013, 64, 372-378.	1.9	71
60	Laparoscopic Prostatectomy for Prostate Cancer. Surgical Oncology Clinics of North America, 2013, 22, 125-141.	1.5	9
61	11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction. Journal of Nuclear Medicine, 2013, 54, 699-706.	5.0	81
62	Impact of surgeon and volume on extended lymphadenectomy at the time of robotâ€assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (<scp>IRCC</scp>). BJU International, 2013, 111, 1075-1080.	2.5	49
63	The optimal management of T1 high-grade bladder cancer. Canadian Urological Association Journal, 2013, 3, 188.	0.6	17
64	Percent Free PSA. , 2013, , 51-60.		0
65	Population Based Analysis of the Increasing Incidence of Kidney Cancer in the United States: Evaluation of Age Specific Trends From 1975 to 2006. Journal of Urology, 2012, 187, 32-38.	0.4	45
66	Renal Functional and Perioperative Outcomes of Off-clamp Versus Clamped Robot-assisted Partial Nephrectomy: Matched Cohort Study. Urology, 2012, 80, 838-844.	1.0	38
67	Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pT1 renal cell carcinoma. BMC Urology, 2012, 12, 11.	1.4	33
68	Description of a multicenter safety checklist for intraoperative hemorrhage control while clamped during robotic partial nephrectomy. Patient Safety in Surgery, 2012, 6, 8.	2.3	13
69	Bladder Lymphoma. Journal of Urology, 2012, 188, 269-270.	0.4	8
70	Population Based Comparative Effectiveness of Transurethral Resection of the Prostate and Laser Therapy for Benign Prostatic Hyperplasia. Journal of Urology, 2012, 187, 1341-1345.	0.4	30
71	Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of highâ€grade nonâ€muscle invasive bladder cancer. International Journal of Urology, 2012, 19, 988-993.	1.0	12
72	Prostate Cancer Risk Reduction by Chemoprevention. , 2012, , 143-152.		O

#	Article	IF	CITATIONS
73	Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Guérin Plus Interferon-α. Journal of Urology, 2011, 185, 67-71.	0.4	24
74	The prognostic impact of an abnormal initial renal ultrasound on early reflux resolution. Journal of Pediatric Urology, 2011, 7, 462-466.	1.1	14
75	Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in Situ. Journal of Urology, 2011, 186, 817-823.	0.4	41
76	Re: Active Surveillance Compared with Initial Treatment for Men with Low-Risk Prostate Cancer: A Decision Analysis. European Urology, 2011, 59, 883-884.	1.9	1
77	Traumatic Urethral Injury without Pelvic Fracture in an Adult Female. Scientific World Journal, The, 2010, 10, 308-310.	2.1	6
78	Giant Renal Angiomyolipoma without Fat Density on CT Scan: Case Report and Review of the Literature. Scientific World Journal, The, 2010, 10, 1334-1338.	2.1	15
79	Hepatocellular Carcinoma Masquerading as a Large Renal Mass with Hepatic Invasion. Scientific World Journal, The, 2010, 10, 301-307.	2.1	2
80	URETERAL DUPLICATION, ECTOPY, AND URETEROCELES. , 2010, , 337-352.		3
81	Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2010, 184, 1915-1919.	0.4	107
82	Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Plus Interferon α-2b Therapy for Nonmuscle Invasive Bladder Cancer in Patients With Prosthetic Devices. Journal of Urology, 2010, 184, 1920-1924.	0.4	9
83	Review of Topical Treatment of Upper Tract Urothelial Carcinoma. Advances in Urology, 2009, 2009, 1-6.	1.3	7
84	Combination of BCG and interferon intravesical immunotherapy: an update. World Journal of Urology, 2009, 27, 343-346.	2.2	18
85	Rare Variant of Bladder Exstrophy Associated With Urethral, Bladder, and Colonic Duplication. Urology, 2009, 73, 928.e1-928.e3.	1.0	7
86	Supernumerary Kidney in a Child With OEIS Complex. Urology, 2009, 74, 305-307.	1.0	18
87	Validation of a Prognostic Calculator for Prediction of Early Vesicoureteral Reflux Resolution in Children. Journal of Urology, 2009, 182, 687-691.	0.4	18
88	Gleason score and laterality concordance between prostate biopsy and prostatectomy specimens. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2009, 35, 559-564.	1.5	15
89	The optimal management of T1 high-grade bladder cancer. Canadian Urological Association Journal, 2009, 3, S188-92.	0.6	21
90	Abnormal Renal Scans and Decreased Early Resolution of Low Grade Vesicoureteral Reflux. Journal of Urology, 2008, 180, 1643-1647.	0.4	34

#	Article	IF	CITATIONS
91	Adding Renal Scan Data Improves the Accuracy of a Computational Model to Predict Vesicoureteral Reflux Resolution. Journal of Urology, 2008, 180, 1648-1652.	0.4	24
92	Prevalence of Delayed Clinician Response to Elevated Prostate-Specific Antigen Values. Mayo Clinic Proceedings, 2008, 83, 439-445.	3.0	19
93	Symptomatic Calcification of Subureteral Collagen Ten Years After Injection. Urology, 2007, 69, 982.e1-982.e2.	1.0	15
94	Efficacy of Transcutaneous Electrical Nerve Stimulation in Children with Overactive Bladder Refractory to Pharmacotherapy. Urology, 2007, 70, 980-983.	1.0	56
95	Indiana pouch stone formation caused by a long-forgotten metallic ball bearing. Canadian Journal of Urology, 2007, 14, 3705-6.	0.0	0
96	KIDNEYS WITH REFLUX NEPHROPATHY MAINTAIN RELATIVE RENAL FUNCTION AFTER URETERAL REIMPLANTATION. Journal of Urology, 2005, 174, 1606-1608.	0.4	12